<DOC>
	<DOCNO>NCT00219843</DOCNO>
	<brief_summary>The objective study investigate safety intralesional ( IL ) PV-10 treatment metastatic melanoma . This study also include preliminary assessment response treat untreated lesion clinical evaluation follow-up 12 24 week follow IL PV-10 treatment .</brief_summary>
	<brief_title>Intralesional PV-10 Chemoablation Metastatic Melanoma</brief_title>
	<detailed_description>This two center , open label , ascend dose study . Subjects least two measurable melanoma lesion receive single intralesional injection 10 % PV-10 solution one twenty ( 20 ) target lesion . Additionally , one three measurable untreated non-target lesion follow assessment bystander response . Systemic locoregional adverse event monitor study interval . Dose escalation make subject first dose level Grade 3 non-hematological Grade 4 hematological toxicity period two week PV-10 administration . Subject accrual PV-10 administration second dose level stop 1 subject treatment relate Grade 3 non-hematological Grade 4 hematological toxicity within period two week PV-10 administration .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>Histologically cytologically confirm metastatic melanoma , American Joint Committee Cancer ( AJCC ) Stage III ( regional lymph node metastasis , intransit metastasis satellite metastasis ) Stage IV ( distant metastasis ) Measurable disease least two lesion , lesion ≤ 6 cm diameter Performance status : ECOG 02 Life expectancy : least 6 month Hematopoietic : White blood cell count ( WBC ) least 3000/mm3 Absolute neutrophil count ( ANC ) least 1.5 ( 1,500/mm3 ) Platelet count least 100,000/mm3 Renal function : Creatinine ≤ 2.0 mg/dL Hepatic function : Bilirubin ≤ 2.0 mg/dL AST/ALT ≤ 3 time upper limit normal ( ULN ) Cardiovascular function : No major cardiovascular disease Thyroid function : T3 ( serum triiodothyronine ) , T4 ( serum thyroxine ) THS ( serum thyrotropin ) within normal limit Immunological function : Adequate immune system function opinion investigator Radiation therapy within 4 week study lesion within 12 week Chemotherapy systemic cancer therapy within 4 week ( 6 week nitrosoureas mitomycin ) regional chemotherapy ( limb infusion perfusion ) within 12 week Local treatment ( e.g. , surgery , cryotherapy , radiofrequency ablation ) treatment area within 4 week Investigational agent within 4 week ( 5 halflives ) Antitumor vaccine therapy within 12 week Concurrent illness : Severe diabetes extremity complication due diabetes Significant concurrent disease illness , psychiatric disorder , alcohol chemical dependence would , opinion investigator , compromise subject safety compliance interfere interpretation study result Thyroid autoregulatory dysfunction , include thyroid disease ( subclinical ongoing ) , goiter , partial thyroidectomy , prior radioiodine surgicallytreated Graves ' hyperthyroidism , cystic fibrosis Pregnancy fertile female subject use effective contraception Concurrent medication : Subjects take medication significant risk photosensitization , thiazide , within one week ( 5 halflives ) study treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Stage III IV melanoma</keyword>
</DOC>